T-Cell Lymphoma Pipeline Grows as 90+ Pharma Companies Advance Novel Therapies, Finds DelveInsight | Soligenix, CStone Pharmaceuticals, Corvus Pharmaceuticals, Bristol-Myers Squibb, March Biosciences

DelveInsight's "T-Cell Lymphoma - Pipeline Insight, 2026" report provides comprehensive insights about 90+ companies developing several pipeline drugs in the T-Cell Lymphoma pipeline landscape. It covers the T-cell lymphoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the T-Cell Lymphoma treatment landscape. Learn more about the evolving T-cell lymphoma pipeline today @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the T-Cell Lymphoma Pipeline Report

• In December 2025, Secura Bio reported progress on its Phase III TERZO trial, with an interim data readout expected in early 2027 based on enrollment.
• In December 2025, Innate Pharma indicated that data from its Phase II PTCL study are expected by the end of 2026.
• In December 2025, Secura Bio presented extended follow-up analyses and safety data from its Phase II PRIMO trial at the American Society of Hematology (ASH) Annual Meeting.
• In November 2023, March Biosciences received a competitive grant from CPRIT to support the upcoming Phase II clinical trial of its CAR-T therapy MB-105 for relapsed and refractory T-cell lymphomas.
• T-cell lymphomas are rare subtypes of non-Hodgkin lymphoma that generally have a poorer prognosis than B-cell lymphomas and often affect adults in their mid-60s.
• DelveInsight's T-Cell Lymphoma Pipeline Insight report monitors over 90 companies and more than 90 pipeline drugs currently in global development.
• Soligenix holds one of the most clinically advanced candidates with HyBryte (SGX301) in Phase III, representing a significant photodynamic topical therapy for cutaneous T-cell lymphoma.

Download for updates and the latest revolution in T-Cell Lymphoma care @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

T-Cell Lymphoma Emerging Drugs Profile

• HyBryte (SGX301): Soligenix
HyBryte is a first-in-class photodynamic therapy utilizing synthetic hypericin, a potent photosensitizer. The drug is topically applied to skin lesions, taken up by malignant T-cells, and subsequently activated by safe, visible fluorescent light. Its pivotal Phase III FLASH study showed a statistically significant response after 6 weeks of treatment, with further improvement noted after 12 weeks. HyBryte has received both Orphan Drug and Fast Track designations from the FDA for the treatment of cutaneous T-cell lymphoma.

• MB-105: March Biosciences
MB-105 is a first-in-class autologous chimeric antigen receptor (CAR) T-cell therapy. This innovative cell therapy is designed to replace T-lymphocytes and target relapsed and refractory T-cell lymphomas. March Biosciences is advancing MB-105 through a Phase II clinical trial, supported by competitive grants for its continued clinical development. Currently, the therapy is being evaluated for its efficacy and safety in patients who have failed prior systemic treatments.

• Soquelitinib: Corvus Pharmaceuticals
Soquelitinib is a first-in-class oral small molecule inhibitor targeting interleukin-2-inducible T-cell kinase (ITK). By inhibiting Emt protein-tyrosine kinase, soquelitinib aims to address the dysregulated signaling pathways in aggressive lymphomas. It is currently undergoing evaluation in a registrational Phase III clinical trial for patients with relapsed or refractory peripheral T-cell lymphoma. The therapy has been granted Orphan Drug and Fast Track designations by the FDA, reflecting the urgent unmet need in this patient population.

For more information on the T-Cell Lymphoma Emerging Drugs Profile, download DelveInsight's comprehensive T-Cell Lymphoma Pipeline Insight report @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The T-Cell Lymphoma Pipeline Report Provides

• Detailed insights about companies developing therapies for T-Cell Lymphoma, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for T-cell lymphoma treatment.
• T-cell lymphoma companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the T-cell lymphoma market.

Learn more about T-Cell Lymphoma drug opportunities in our comprehensive T-cell lymphoma pipeline report @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

T-Cell Lymphoma Companies and Competitive Landscape

There are 90+ key companies, including Soligenix, CStone Pharmaceuticals, Corvus Pharmaceuticals, Bristol-Myers Squibb, March Biosciences, Innate Pharma, Secura Bio, and others, developing therapies for T-Cell Lymphoma, with Soligenix and Corvus Pharmaceuticals having candidates in the advanced Phase III stage.

DelveInsight's T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

T-Cell Lymphoma products have been categorized under various Molecule types such as:

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in T-Cell Lymphoma treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the T-Cell Lymphoma Pipeline Report

• Coverage: Global
• T-Cell Lymphoma Companies: Soligenix, CStone Pharmaceuticals, Corvus Pharmaceuticals, Bristol-Myers Squibb, March Biosciences, Innate Pharma, Secura Bio, and others.
• T-Cell Lymphoma Therapies: HyBryte (SGX301), MB-105, soquelitinib, sugemalimab, SLS009, and other pipeline candidates.
• T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
• T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.